62780-80-7

Basic information

• Product Name: 1H-Benzimidazole-1-butanol(9CI)
• Synonyms: 1H-Benzimidazole-1-butanol(9CI)
• CAS NO: 62780-80-7
• Molecular Formula: C11H14N2O
• Molecular Weight: 190.24
• Product Categories: BENZIMIDAZOLE
• Mol File: 62780-80-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Benzimidazole-1-butanol(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-1-butanol(9CI)(62780-80-7)
• EPA Substance Registry System: 1H-Benzimidazole-1-butanol(9CI)(62780-80-7)

Safety Data

• Hazardous Substances Data: 62780-80-7(Hazardous Substances Data)

Upstream product

• 51-17-2 benzoimidazole 
• 928-51-8 4-Chloro-1-butanol 
• 19018-22-5 1-allylbenzimidazole 
• 201230-82-2 carbon monoxide 
• 41302-05-0 1-chloro-4-tetrahydropyranyloxybutane 

Relevant articles and documents

Development of a Benzimidazole-Derived Bidentate P,N-Ligand for Enantioselective Iridium-Catalyzed Hydrogenations

The development of a novel benzimidazole-derived bidentate P,N-ligand and its application in Ir-catalyzed hydrogenation is described. The ligand backbone was obtained through a one-pot tandem hydroformylation-cyclization sequence and the enantiomers of the generated alcohol were separated by chiral HPLC. By comparing the experimentally obtained CD spectra of the enantiomers with the simulated spectra generated from time-dependent DFT calculations, the absolute configuration could be obtained. The chiral alcohols could further be isolated on a larger scale after transesterification by using Candida Antarctica lipase B (Novozym 435) and could subsequently be converted into the corresponding chiral P,N-ligand by reaction with ClPPh2. The coordination properties of the racemic P,N-ligand were investigated and the molecular structure of the RhI complex [(P,N)Rh(CO)Cl] was determined by X-ray crystal structure analysis. The corresponding chiral cationic IrI complex was used as catalyst for the enantioselective hydrogenation of prochiral N-phenyl-(1-phenylethylidene)amine and trans-α-methylstilbene. For the N-aryl-substituted imine, enantiomeric excesses of only 10 % were obtained, whereas the unfunctionalized olefin could be hydrogenated with enantiomeric excesses of up to 90 %. Interestingly, the modular synthetic access to the P,N-hybrid system described here allows facile modification of the ligand structure, which should extend the scope of such novel P,N-ligands for asymmetric catalytic conversions to a large extent in the future.

1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives

Novel 1-[(heterocyclyl)alkyl]-4-diarylmethoxy piperidine derivatives are disclosed having the formula STR1 where n is 2-6, Ar1 and Ar2 are aryl and B is a substituted benzimidazolyl radical. These compounds are useful for their antianaphylactic and antihistaminic properties. Specific claimed compounds are 1-{3-[4-(diphenylmethoxy)-1-piperidinyl]-propyl}-1,3-dihydro-2H-benzimidazol-2-one, 1-{2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl}1-, 3-dihydro-2H-benzimidazol-2-one, and 1-{4-[4-(diphenylmethoxy)-1-piperidinyl]butyl}-1,3-dihydro-2H-benzimidazol-2-one.